Evidence map›Paper›PMID 34956847›Full record

ArticlePublic health action2021

Isoniazid preventive therapy in child household contacts of adults with active TB in Bamako, Mali.

M Tolofoudie, A Somboro, B Diarra, Y S Sarro, H B Drame, A C G Togo, M Sanogo, A Dembele, T Togun, E Nkereuwem and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health action, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

M TolofoudieUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
A SomboroUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
B DiarraUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Y S SarroUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
H B DrameUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
A C G TogoUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
M SanogoUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
A DembeleDepartment of Paediatrics, University Teaching Hospital of Gabriel Toure, Bamako, Mali.
T TogunVaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia.
E NkereuwemVaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia.
B BayaUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
B KonateNational Tuberculosis Control Program, Ministry of Health and Public Hygiene, Bamako, Mali.
U EgereVaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia.
M TraoreHealth Referral Center Five, Ministry of Health and Social Development, Bamako, Mali.
M MaigaCenter for Innovation in Global Health Technology, Northwestern University, Chicago, IL, USA.
K Saliba-ShawCollaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.
B KampmannVaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia.
S DialloUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
S DoumbiaUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
M SyllaDepartment of Paediatrics, University Teaching Hospital of Gabriel Toure, Bamako, Mali.

Funding

The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental RequestU54EB027049 · NIBIB · NORTHWESTERN UNIVERSITY · PI Chad J Achenbach · 2018 to 2026
$24.0M
Training Program on Operational and Health Services Research for Malaria in MaliD43TW008652 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI SEYDOU DOUMBIA, Alexandre Delamou · 2010 to 2026
$3.1M
FIC NIH HHS D43 TW008652NIBIB NIH HHS U54 EB027049
6 · The paper itself

Abstract

BACKGROUND AND

objectiveIsoniazid preventive therapy (IPT) is known to reduce the risk of developing active TB in about 59% in children aged ⩽15 years. We assessed adherence, completion and adverse events among children who were household contacts of a newly diagnosed adult with smear-positive TB in Bamako, Mali.

methodsChildren aged <15 years living in the same house with an adult smear-positive index case were enrolled in the study in the Bamako Region after consent was obtained from the parent or legal guardian. Adherence was assessed based on the number of tablets consumed during 6 months.

resultsA total of 260 children aged <15 years were identified as household contacts of 207 adult patients with smear-positive TB during the study period. Among all child contacts, 130/260 (50.0%) were aged 0-4 years and were eligible for IPT; 128/130 (98.5%) were started on IPT and 83/128 (64.8%) completed with good adherence at the end of the 6 months, and without any significant adverse events.

conclusionWe successfully implemented IPT with good acceptance, but low completion rate. The Mali National TB Program and partners should expand this strategy to reach more children in Bamako and the whole country and create greater awareness in the population.

Indexed as

Bamakochildhood TBIPTMali

Identifiers

PMID34956847
PMCPMC8680184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.